Q-omics provides the consensus-scored MOSPD1 profile across patient tissues and cancer cell-line models. MOSPD1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, MOSPD1 is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, MOSPD1 protein abundance shows 21,492 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight MESO, LIHC, and LSCC as cancer lineages where MOSPD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MOSPD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MOSPD1 survival associations across molecular data types. MOSPD1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (2) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MOSPD1 RNA expression–survival associations across cancer types. High MOSPD1 expression shows unfavorable associations in MESO, LGG, STAD and BRCA, but favorable associations in KIRC and ACC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify MESO as the clearest survival context for MOSPD1 RNA expression.
This table summarizes MOSPD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 6. The strongest signals are observed in LIHC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MOSPD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MOSPD1 shows higher tumor expression in LIHC, BLCA, LUAD, COAD, BRCA and CHOL. The LIHC box plot shows higher MOSPD1 RNA expression in tumor versus normal tissue (log2 FC = +1.213, t-test p < 0.001).
This table shows molecular features associated with MOSPD1 in patient tissues and cancer cell lines. In patient samples, MOSPD1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, MOSPD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in CNS and BLOOD_Lymphoma.
